


2-7-01

CP 1617

PURSUANT TO 37 C.F.R. § 1.10, I HEREBY CERTIFY THAT THIS PAPER (ALONG WITH ANY PAPER IDENTIFIED AS BEING ATTACHED OR ENCLOSED) IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE ON THE DATE SHOWN BELOW IN AN ENVELOPE ADDRESSED as "Express Mail Post Office to Addressee" TO: COMMISSIONER OF PATENTS WASHINGTON D.C. 20231
Express Mail # EH503193595US ON: February 5, 2001
BY: [Signature]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PC9919A
121*241

#6/B
#KD
2-15-01

RECEIVED

FEB 09 2001

TECH CENTER 1600/2900

JAN BUCH ET AL)
SERIAL NO: 09/512,914)
FILED: FEBRUARY 25, 2000)
FOR: THERAPEUTIC COMBINATION)

ART UNIT: 1617

EXAMINER: S. A. Jiang

Assistant Commissioner of Patents
Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Office Action dated January 4, 2001, please enter the following amendments and remarks into the record.

IN THE CLAIMS:

✓
Cancel claims 4 through 83 without prejudice.

Add the following claims:

118. The pharmaceutical composition of claim 1 comprising the hemicalcium salt of atorvastatin.
119. The kit of claim 84 comprising the hemicalcium salt of atorvastatin.
120. The method of claim 99 comprising the hemicalcium salt of atorvastatin.